A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
Status:
UNKNOWN
Trial end date:
2024-03-26
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, and double-blind study to evaluate the safety and bridging PK profile of FB825 for single SC administration in healthy adults.